Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy
dc.contributor.author | Wong, Stephen N. | en_US |
dc.contributor.author | Chu, Chi-Jen | en_US |
dc.contributor.author | Wai, Chun-Tao | en_US |
dc.contributor.author | Howell, Terese | en_US |
dc.contributor.author | Moore, Charles | en_US |
dc.contributor.author | Fontana, Robert John | en_US |
dc.contributor.author | Lok, Anna Suk-Fong | en_US |
dc.date.accessioned | 2007-09-20T18:20:29Z | |
dc.date.available | 2008-04-03T18:52:37Z | en_US |
dc.date.issued | 2007-03 | en_US |
dc.identifier.citation | Wong, Stephen N.; Chu, Chi-Jen; Wai, Chun-Tao; Howell, Terese; Moore, Charles; Fontana, Robert J.; Lok, Anna S.F. (2007). "Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy." Liver Transplantation 13(3): 374-381. <http://hdl.handle.net/2027.42/55976> | en_US |
dc.identifier.issn | 1527-6465 | en_US |
dc.identifier.issn | 1527-6473 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/55976 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17318855&dopt=citation | en_US |
dc.description.abstract | Hepatitis B virus (HBV) recurrence rates of 0-16% had been reported in patients maintained on nucleoside analogues (NA) after hepatitis B immunoglobulin (HBIG) discontinuation after orthotopic liver transplantation (OLT). However, follow-up in most studies was short. We aimed to determine the long-term risk of HBV recurrence using this strategy. All HBV patients who received ≥7 doses of intravenous HBIG after OLT, with no HBV recurrence while receiving HBIG, and who eventually discontinued HBIG and were maintained on NA, were included. HBV recurrence was defined as HBsAg-positive or HBV DNA ≥5 log copies/mL on 2 consecutive occasions. Twenty-one patients met the inclusion criteria. Immediate post-OLT prophylaxis was combination HBIG and NA in 15 patients, whereas 6 patients received HBIG monotherapy for 62-109 months before NA was added. HBIG was discontinued a median of 26 (range, 0.2-121) months after OLT. Median follow-up post-HBIG discontinuation was 40 (range, 5-51) months. Only 1 patient, who had 12 months of HBIG and was noncompliant to NA therapy, had HBV recurrence, 34 months after HBIG discontinuation. One patient had HBV DNA of 3.3 log copies/mL 47 and 48 months after HBIG discontinuation but remained HBsAg-negative. Lamivudine-resistant mutations were detected in both patients. Probability of HBV recurrence was 0% and 9% at 2 and 4 years after HBIG discontinuation. Three patients had 1-2 episodes of transiently detectable HBV DNA. All were HBV DNA and HBsAg negative on repeated tests over a period of 2-36 months. Maintenance therapy with NA after discontinuation of long-term HBIG therapy is associated with a low risk of HBV recurrence after OLT in compliant HBV patients. Liver Transpl 13:374–381, 2007. © 2007 AASLD. | en_US |
dc.format.extent | 107665 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Surgery | en_US |
dc.title | Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Gastroenterology, University of Michigan, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Division of Gastroenterology, University of Michigan, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Division of Gastroenterology, University of Michigan, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Division of Gastroenterology, University of Michigan, Ann Arbor, MI ; Department of Surgery, University of Michigan, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Division of Gastroenterology, University of Michigan, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Division of Gastroenterology, University of Michigan, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Division of Gastroenterology, University of Michigan, Ann Arbor, MI ; Telephone: 734-615-4628; FAX: 734-936-7392 ; Anna Lok, Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109-0362 | en_US |
dc.identifier.pmid | 17318855 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/55976/1/21041_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/lt.21041 | en_US |
dc.identifier.source | Liver Transplantation | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.